^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    BAT1308

    i
    Other names: BAT1308, BAT-1308, BAT 1308
    Associations

    News

    Trials
    Company:
    Bio-Thera Solutions
    Drug class:
    PD1 inhibitor
    Related drugs:
    Associations

    News

    Trials
    4ms
    BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer (clinicaltrials.gov)
    P2/3, N=5, Terminated, Bio-Thera Solutions | N=140 --> 5 | Trial completion date: Dec 2025 --> Aug 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Nov 2025 --> May 2025; Due to the adjustment of our company's research and development strategy, we are now prematurely terminating this project.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Mismatch repair • dMMR
    |
    carboplatin • paclitaxel • BAT1308
    4ms
    A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=112, Active, not recruiting, Bio-Thera Solutions | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    BAT8008 • BAT1308
    8ms
    BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer (clinicaltrials.gov)
    P2/3, N=140, Active, not recruiting, Bio-Thera Solutions | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Nov 2024 --> Nov 2025
    Trial completion date • Trial primary completion date • Mismatch repair • dMMR
    |
    carboplatin • paclitaxel • BAT1308
    10ms
    BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer (clinicaltrials.gov)
    P2/3, N=526, Recruiting, Bio-Thera Solutions | Not yet recruiting --> Recruiting | Trial completion date: Aug 2024 --> Jan 2027 | Trial primary completion date: Apr 2024 --> Sep 2026
    Enrollment open • Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Avastin (bevacizumab) • cisplatin • carboplatin • paclitaxel • Avzivi (bevacizumab-tnjn) • BAT1308
    12ms
    Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy with BAT1308 in Advanced Solid Tumors (clinicaltrials.gov)
    P1, N=148, Active, not recruiting, Bio-Thera Solutions | Recruiting --> Active, not recruiting | Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Dec 2023 --> Mar 2025
    Enrollment closed • Trial completion date • Trial primary completion date • Metastases
    |
    PD-L1 (Programmed death ligand 1)
    |
    BAT1308
    1year
    A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=112, Recruiting, Bio-Thera Solutions | N=204 --> 112
    Enrollment change • Metastases
    |
    BAT8008 • BAT1308
    1year
    A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=204, Recruiting, Bio-Thera Solutions | N=50 --> 204
    Enrollment change • Metastases
    |
    BAT8008 • BAT1308
    1year
    BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer (clinicaltrials.gov)
    P2/3, N=140, Active, not recruiting, Bio-Thera Solutions | Recruiting --> Active, not recruiting | Trial completion date: Oct 2027 --> Dec 2024 | Trial primary completion date: Sep 2024 --> Nov 2024
    Enrollment closed • Trial completion date • Trial primary completion date • Combination therapy • Mismatch repair • Metastases
    |
    carboplatin • paclitaxel • BAT1308
    over1year
    A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=50, Recruiting, Bio-Thera Solutions | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    BAT8008 • BAT1308
    over1year
    A Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy of the Combination of BAT8008 With BAT1308 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=50, Not yet recruiting, Bio-Thera Solutions
    New P1/2 trial
    |
    BAT8008 • BAT1308
    over1year
    BAT1308 in Combination With Platinum-containing Chemotherapy is Used for the First-line Treatment of Advanced or Recurrent dMMR Endometrial Cancer (clinicaltrials.gov)
    P2/3, N=140, Recruiting, Bio-Thera Solutions
    New P2/3 trial • Combination therapy • Mismatch repair • Metastases
    |
    carboplatin • paclitaxel • BAT1308
    over1year
    Assessment of Safety, Tolerability and Pharmacokinetics With BAT4706 and BAT1308 in Advanced Solid Tumors Patients (clinicaltrials.gov)
    P1, N=210, Recruiting, Bio-Thera Solutions | Not yet recruiting --> Recruiting
    Enrollment open • Metastases
    |
    BAT1308